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Summary The effect of charge modification of photoimmunoconjugates (PICs) on their biodistribution in a xenograft model of ovarian cancer
was investigated. Chlorin.6 e6 was attached site specifically to the F(ab')2 fragment of the murine monoclonal antibody OC125, directed
against human ovarian cancer cells, via poly-1-lysine linkers carrying cationic or anionic charges. Preservation of immunoreactivity was
checked by enzyme-linked immunosorbent assay (ELISA). PICs were radiolabelled with 1251 and compared with non-specific rabbit IgG PICs
after intraperitoneal (i.p.) injection into nude mice. Samples were taken from normal organs and tumour at 3 h and 24 h. Tumour to normal 1251
ratios showed that the cationic OC125F(ab')2 PIC had the highest tumour selectivity. Ratios for ce6 were uniformly higher than for 1251,
indicating that ce6 became separated from 1251. OC125F(ab')2 gave highest tissue values of 1251, followed by cationic OC125F(ab')2 PIC; other
species were much lower. The amounts of cee delivered per gram of tumour were much higher for cationic OC125F(ab')2 PIC than for other
species. The results indicate that cationic charge stimulates the endocytosis and lysosomal degradation of the OC125F(ab')2-pl-cee that has
bound to the i.p. tumour. Positively charged PICs may have applications in the i.p. photoimmunotherapy of minimal residual ovarian cancer.
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Ovarian cancer ranks as the fifth most common malignancy in
American women. In this country, approximately 1 in 70 women
will develop ovarian cancer in their lifetime, and 1 in 100 will die
of the disease (Parker et al, 1996). It currently has the highest
fatality to case ratio of all the gynaecological malignancies,
primarily because most patients present with late-stage disease.
Overall 5-year survival for ovarian cancer is only 38%. Chemo-
therapy is the most frequently used adjunctive treatment following
surgical debulking. Despite advances in chemotherapeutic regi-
mens (Ozols, 1995), there has been little or no change in the 5-year
survival over the past 10 years.
Photodynamic therapy (PDT) is being considered as a useful
weapon in the cancer therapy armament (Fisher et al, 1995; Hasan
and Parrish, 1996). It involves the systemic or intraperitoneal (i.p.)
administration of a non-toxic drug called a photosensitizer (PS),
which to some extent preferentially localizes in the tumour
(Henderson and Dougherty, 1992). When the tumour is irradiated
with the wavelength of light that is absorbed by the PS, and in the
presence ofoxygen, toxic oxygen species are produced, which can
cause tissue necrosis by a combination of mechanisms (including
vascular shutdown, direct tumour cell killing and immune stimula-
tion). PDT could be an attractive approach to eliminating the
minimal residual disease after surgical debulking ofovarian cancer
(DeLaney et al, 1993; Molpus et al, 1996a). Because of the wide
i.p. dissemination ofthe disease, the irradiation must be over a large
area of the intraperitoneal surface, including intestines and other
abdominal organs (Veenhuizen et al, 1994). For this reason, it is
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important to investigate ways of increasing the specificity of the
photosensitizer for the tumour, in order to spare damage to the
normal tissues within theperitoneal cavity (Veenhuizen etal, 1994).
One way to improve tumour specificity ofphotosensitizers is to
link them covalently with tumour-targeting monoclonal antibodies
(Hasan, 1992; Yarmush et al, 1993). OC125 is a murine mono-
clonal antibody that recognizes the cell-surface antigen CA 125, a
1000-kDa glycoprotein (Hosono et al, 1992) expressed by 85% of
non-mucinous epithelial ovarian cancers (Karlan et al, 1988).
Conjugates of OC125 with radioisotopes (Haisma et al, 1988;
Muto et al, 1992) and cytotoxic drugs (Beck et al, 1994) have been
administered i.p. to target ovarian cancer in both animals and
humans. We have previously reported on the preparation (Goff et
al, 1992), in vitro reactions (Goffet al, 1991) and in vivo biodistri-
bution (Goff et al, 1994) of a conjugate between ce6 ethylenedi-
amine monoamide (a derivative of ce6) and intact OC125, which
had a negative charge owing to the use of a polyglutamic acid
linker. Although the data on the reactions of this PIC with cell
lines in vitro and with cells derived from tumour tissue ex vivo
were encouraging, it gave only modest tumour to normal ratios
and tumour uptake in vivo. As part of our ongoing effort to opti-
mize the tumour selectivity and the uptake of PS delivered by
PICs, this study has investigated the effect ofcharge modification
of PICs derived from the F(ab')2 fragment of OC125 on their
biodistribution in a new xenograft model of ovarian cancer.
Because the effect ofcharge on the i.p. biodistribution ofimmuno-
conjugates is unknown, and because the use of F(ab')2 fragments
shows advantages over intact IgG molecules in terms of penetra-
tion into tissue (Buchegger et al, 1990), we have developed a new
conjugation strategy applicable to F(ab')2 fragments and in which
the charge can be either positive or negative. The PICs bearing
either polycationic or polyanionic charges were prepared, labelled
with 1251 and injected i.p. into a murine model derived a human
837838 LR Duska etal
ovarian carcinoma cell line (NIH:OVCAR-5). Biodistribution of
both the protein moiety and the photosensitizer moiety were
measured independently via tissue content of 1251 radioactivity and
ce6 fluorescence respectively.
MATERIALS AND METHODS
Mice
Female Swiss nude mice (Cox Breeding Laboratories, Cambridge,
MA, USA) 6-8 weeks old received proper care and maintenance
according to institutional guidelines. They had continuous access
to food and water, which was taken ad libitum. Throughout the
experiments mice were housed in laminar flow racks under
specific pathogen-free conditions and were monitored daily for
general health status.
Tumour cells
NIH:OVCAR-5 cells were purchased from DrTom Hamilton (Fox
Chase Cancer Institute, Philadelphia, PA, USA). Cells were grown
in RPMI-1640 medium supplemented with 10% heat-inactivated
fetal calf serum (FCS) and 1% Hepes and were maintained in an
incubator (Queue Cell Culture Incubator, model 2720; Queue
Systems, Parkersburg, WV, USA) at 370C in an atmosphere of5%
carbon dioxide. Cells were harvested for injection during the log
growth phase, when growth was 80-85% confluent. For harvest
and transplantation, cells were trypsinized (trypsin-EDTA; Gibco,
Grand Island, NY, USA), centrifuged at 20°C for 10 min at 148 g
(model RT6000; Sorvall Centrifuges, Dupont, Wilmington, DE,
USA) and resuspended in phosphate-buffered saline without
calcium or magnesium (PBS, Gibco) for counting.
Antibodies
Monoclonal antibody OC125 F(ab')2 was a kind gift from
Centacor (Malvem, PA, USA) and rabbit IgG was purchased from
Sigma (St Louis, MO, USA). Both proteins were radiolabelled
with 1251I by the lodogen procedure (Salacinski et al, 1981). The
specific activity of the OC125F(ab')2 was 8.7 MBq mg-', while
that ofthe rabbit IgG was 2.1 MBq mg-'.
Conjugation procedure
The procedure has been described in detail elsewhere (Hamblin et
al, 1996). Briefly, poly-L-lysine (average mol. wt. 25 000) was
treated in dimethyl sulphoxide (DMSO) with the N-hydroxysuc-
cinimide ester of ce6 to give pl-ce6' This was then reacted with
pyridyldithiopropionic acid N-hydroxysuccinimide ester to form
the functionalized derivative pl-ce6-SPDP. This was then split into
two parts and one part was treated with an excess of succinic
anhydride to give the negatively charged functionalized pl-ce6-
succ-SPDP. [125I]OC125F(ab')2 or 1251-labelled rabbit IgG was
reduced for 1 h with 5 mm mercaptoethylamine hydrochloride,
dialysed and then reacted with either pl-ce6-SPDP or pl-ce6-succ-
SPDP to form the cationic and anionic PICs respectively. When
p1-ce6 was treated with succinic anhydride, pl-ce6-succ was
obtained. The conjugates were purified by chromatography on
Sephadex G200 columns and characterized by absorption and
fluorescence spectrophotometry, and by polyacrylamide gel
electrophoresis. The structures of the cationic PIC OC125F(ab')2-
p1-ce6 and the anionic PIC OC125F(ab')2-pl-cg6-succ are shown in
Figure 1.
0 >,COOH
0
Cationic OC125F(ab')2pI-ce6 Anionic OC125F(ab')2p1-ce6-succ
Figure 1 Chemical structures of the cationic PICOC125F(ab')2-pl-c, and the anionic PICOC125F(ab')2-pl-cW-succ
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Figure 2 Determination of immunoreactivity of MAbs and PICs by ELISA
on fixed OVCAR-5 cells M,OC125F(ab')2, OI, OC125F(ab')2-pl-ce6;
0, OC125F(ab')2-pl-cW6-succ; O, mouse IgG
ELISAs
OVCAR-5 cells were grown in a 96-well plate (10 000 cells ml-')
to which was added RPMI containing 5% FCS. Cells were fixed
with 0.025% glutaraldehyde, washed three times with PBS and
blocked with 1% FCS, 1% glycine and 0.02% sodium azide. The
MAb, conjugate or control mouse IgG was serially diluted from
0.1 mg ml-' to 10 ng ml' in PBS and 0.1 ml of protein solution
was added and allowed to incubate for 2 h at room temperature.
The MAb was removed and the fixed cells washed three times
with PBS containing 0.05% Tween 20. To each well was added 0.1
ml of F(ab')2 fragment horseradish peroxidase-conjugated rabbit
anti-mouse IgG (Zymed) diluted 1:400 in PBS containing 0.05%
bovine serum albumin (BSA) and 0.05% Tween 20. This was
allowed to incubate for 2 h, removed, washed three times with
PBS/0.05% Tween 20 and 0.1 ml of a freshly prepared solution of
1,2-phenylenediamine (0.4 mg ml-') in 0.05 M sodiumcitrate, 0.15
M sodium phosphate, pH 6, containing 0.032% 30% hydrogen
peroxide was added. This was allowed to incubate in the dark for 1
h, after which 0.05 ml of4 M sulphuric acid was added to terminate
the reaction. The absorbance was read at 492 nm in the automatic
plate reader.
Animal model of ovarian cancer
This has been described in detail elsewhere (Molpus et al, 1996b).
Briefly, NIH:OVCAR-5 cells in culture were harvested as
described and the pellet of cells obtained by centrifugation was
suspended in PBS to a concentration of I x 107 cells ml-.
Intraperitoneal injection into female nude mice was performed
with 1 x 107 cells in 1 ml. Within 14 days, the animals developed
small, multifocal tumour nodules throughout the peritoneal cavity.
Twenty-eight days after inoculation, animals developed significant
macroscopic tumour burden in the abdomen and pelvis, at which
time biodistribution studies were performed.
Biodistribution of radiolabelled OC125F(ab')2 PICs and
control conjugates in tumour-bearing nude mice
Twenty-eight days after intraperitoneal injection ofNIH:OVCAR-
5 tumour cells, groups of 12 mice were given i.p. injections of 1251
radiolabelled cationic and anionic OC125F(ab')2 PICs containing
10 jig ofce6 conjugated to approximately 80gg ofMAb in 1 ml of
sterile PBS. Also injected was unconjugated ['251]OC125F(ab')2
(80 jg of protein), unconjugated ['251]rabbit IgG (135 ,ug of
protein), cationic and anionic ['251]rabbit IgG PICs (10 jig of ce6
bound to 135 jig ofprotein), non-radioactivepl-ce6, pl-cee6-succ and
free ce6 (10 jg ofce6 equivalent), all in 1 ml of sterile PBS.
Six mice in each group were sacrificed using inhalation anaes-
thesia at 3-h and 24-h intervals. Two tumour nodules (one from the
pelvis and one from the abdomen) and samples of normal tissues
Table 1 Tumour - normal tissue ratios of 1251 contained per gram of tissue and %ID per g in tumoura (±s.e.m.)
1251 conjugate Time (h) Tumour - Tumour - Tumour - Tumour - Tumour - Tumour - Mean ratio %1D1251
liver kidney intestine skin spleen lung per g tumour
OC125F(ab')2 3 5.7 ±2.3 2.3 ±0.2 3.5 ± 0.7 2.1 ±0.6 1.9 ± 0.3 5.4± 2.1 3.5± 0.4 30.1 ± 1.3
OC125F(ab')2 24 2.7 ± 0.6 2.8 ± 0.2 5.4 ± 0.5 3.0± 1.2 1.4 ± 0.2 4.0± 1.7 3.2± 0.4 38.1 ±2.9
OC125F(ab')2-Pl-c,6 3 5.4 ± 1.2 0.9± 0.1 6.4 ± 1.2 3.3 ± 0.8 4.7±2.5 10.6 ± 5.2 5.2 ± 1.0 25.8 ± 6.5
OC125F(ab')2-PI-c,6 24 4.2 ±2.5 1.5 ± 1.0 2.9± 1.4 3.6 ±3.0 2.6± 1.5 3.3 ± 1.1 3.0 ± 0.4 17.1 ± 1.8
OC125F(ab')2-pI-c,6-succ 3 4.9 ± 1.7 3.6 ± 1.8 3.5 ± 0.9 2.4 ± 0.5 2.4 ± 0.6 2.7 ± 0.5 3.3 ± 0.4 6.3 ± 1.3.
OC125F(ab')2-pI-ce6-succ 24 2.8 ± 0.9 2.4 ± 1.0 7.1 ± 1.7 1.9 ± 0.7 3.0± 1.0 6.0± 0.9 3.9± 0.7 3.8± 0.9
Rabbit IgG 3 2.7 ±0.7 1.5 ±0.5 2.6 ± 0.7 0.7 ± 0.2 1.8 ± 0.5 2.6± 1.0 1.8± 0.2 5.2± 1.6
Rabbit IgG 24 1.1 ±0.5 1.0±0.2 1.5±0.2 0.7±0.1 0.8±0.3 0.8±0.1 0.86±0.1 2.9±0.5
Rabbit IgG-pl-c,6 3 1.1 ±0.4 1.2 ±0.3 3.1 ±0.5 0.7 ± 0.2 0.8 ± 0.3 1.4 ± 0.5 2.2± 0.25 1.9 ± 0.4
Rabbit IgG-pI-ce6 24 1.0 ±0.2 1.0 ±0.2 2.0 ± 0.3 0.4± 0.1 0.6± 0.1 0.9± 0.2 1.3± 0.14 2.0± 0.3
Rabbit IgG-pl-cw6-succ 3 2.7 ± 0.6 1.5 ± 0.4 3.9 ± 0.7 0.9 ± 0.2 2.1 ± 0.5 2.8 ± 0.7 1.5 + 0.1 6.7 ± 2.3
Rabbit IgG-pl-c96-succ 24 1.5 ± 0.3 1.0 ±0.4 1.5 ± 0.2 0.7± 0.1 0.8± 0.2 1.4 ± 0.2 0.9+ 0.1 3.9 ± 0.8
aNude mice bearing i.p. OVCAR-5 tumours (six per time point) were injected with 1.2 x 107 c.p.m. 1251 bound to OC125F(ab')2 alone or conjugated
(approximately 80 9g of protein) or 5 x 106c.p.m. '251-labelled rabbit IgG (approximately 135 9g of protein). After 3 h or 24 h, animals were sacrificed and
samples of tumour and normal tissue removed, weighed and the 1251 determined in a gamma counter. Values are the means of ratios calculated for each of six
mice (each tumour 1251 value was the mean of two separate tumour samples). Mean ratios were calculated by taking the mean of 36 tumour - normal ratios (for
six organs from six mice).
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Figure 3 Biodistribution of 1251 expressed as percentage dose per gram of
tissue taken from tumour-bearing nude mice (A) 3 h and (B) 24 h after
injection of 1.2 x 1 07C.p.M. [1251] 0C125F(ab')2; FL1, [1251]OC125F(ab')2-Pl-C,6;
E2, [1251]0C125F(ab')2-Pl-Ce6SUCC. Values are means (± s.e.m.) from six mice
(tumour mean is of two separate samples from each of six mice)
(skin, liver, kidney, intestine, spleen and lung) were immediately
removed from each mouse, weighed (wet weights were between
25 and 100 mg) and counted in a gamma counter to determine 1251
activity. Following counting, all samples were lyophilized and
suspended in 2 Ml Of N sodium hydroxide containing 0.1%
sodium dodecyl sulphate (SDS). Samples were allowed to dissolve
in the dark for 7 days. Following this, homogenization was
performed by hand as needed. The fluorescence of each sample
was measured with a spectrofluorometer (Fluorolog 2; Spex
Industries, Edison, NJ, USA) (excitation at 400 nm, emission
scanned from 580 to 720 nm). The peak area above the back-
ground was measured and compared with that of standard solu-
tions. The fluorescence of tissue samples from nine Ab-injected
animals was used for the correction of endogenous fluorescence
present in the skin and intestines. No significant endogenous fluo-
rescence was found in tumour or other organs sampled.
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Figure 4 Biodistribution of 1251 expressed as percentage dose per gram of
tissue taken from tumour-bearing nude mice (A) 3 h and (B) 24 h after
injection of 8.9x 106C.p.M. 1251-labelled rabbit IgG; FL, 1251 rabbit IgG-pl-c e6;
r2, '251-labelled rabbit IgG-pl-cW-succ. Values are means (± s.e.m.) from six
mice (tumour mean is of two separate samples from each of six mice)
Statistics
Differences between means were analysed for statistical signifi-
cance by the Student's t-test (P-values < 0.05 were considered
significant). Standard errors of ratios of two means were found by
calculating in quadrature.
RESULTS
Immunoreactivity of PICs
Although the formation of the PICs was carried out by a site-
specific conjugation strategy in order to preserve immunoreac-
tivity, the manipulation of the charge may have affected the antigen
recognition characteristics of the MAb, and ELISAs with fixed
cells were carried out to confirmn that both the cationic and cationic
PICs retained immunoreactivity. As can be seen from Figure 2, the
anionic PICs had the highest affinity for fixed OVCAR-5 cells,
closely followed by the unmodified 0C125F(ab')2 and the anionic
PIC, while the non-specific mouse IgG showed no significant
binding.
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Table 2 Tumour - normal tissue ratios of fluorescence and absolute tumour fluorescence extracted per gram of tissuea (± s.e.m.)
cd Conjugate Time (h) Tumour - Tumour - Tumour - Tumour - Mean ratio Fluor (x 106)
liver kidney intestine skin per gram tumour
Cationic OC125F(ab')2-pl-c,6 3 35.6 ± 15 13.8 ± 5.7 9.7 ± 5.4 15.8 ± 6.8 18.7 ± 4.5 23.2 ± 10.0
Cationic OC125F(ab')2-pl-ce6 24 56.7 ± 22 30.3 ± 19 0.7 ± 0.5 6.8 ± 3.2 23.1 ± 8.1 28.3 ± 9.6
Anionic OC125F(ab')2-pl-cW-succ 3 7.5 ± 4.8 5.6 ± 4.2 0.2 ± 0.1 10.1 ± 9.4 7.7 ± 2.6 3.3±1.9
Anionic OC125F(ab')2-pl-cW-succ 24 36.6 ± 15 14.3 ± 5.3 4.0 ± 1.3 19.5 ±17 18.6 ± 5.8 11.0± 5.0
Cationic rabbit IgG-pl-c.6 3 42.2 ± 30 36.7 ± 19 0.56 ± 0.3 8.2±1.7 22 ± 6.4 7.3 ± 2.7
Cationic rabbit IgG-pl-c.6 24 62.6 ± 20 50 ± 21 1.0 ± 0.5 7.8 ± 3.6 30.4 ± 8.4 7.4 ± 3.0
Anionic rabbit IgG-pl-ce-succ 3 54± 15.7 20± 15 0.7± 0.3 2.3± 1.7 19.3 ±6.6 3.3± 1.7
Anionic rabbit IgG-pl-ce-succ 24 44.4 ± 14 12.4 ± 8.6 2.2 ± 1.5 0.9 ± 0.3 18 ± 5.7 6.3 ± 1.6
Cationicpl-c.6 3 26±12 9.4±0.8 0.26±05 4±2.7 10±2.6 6.5±2.9
Cationicpl-c.6 24 10.7 ±8 3.4± 2.6 0.06 ±.04 0.13 ±.06 3.6± 1.6 3.0±1.2
Anionicpl-cw-succ 3 6.7 ± 3.2 54 ± 26 0.1 ± 0.4 6.2 ± 2.8 16.8 ± 8.3 3.2 ± 0.7
Anionicpl-cW-succ 24 27 ± 24 50 ± 27 0.02 ± .01 0.3 ± 0.2 19.6 ± 1.0 1.3 ± 0.2
Ce6 3 15.7±2.8 38±23 0.14±.05 0.55±.14 13.7±5.2 5.4± 1.0
ce6 24 51 ±19 >100 0.4±0.2 1.9±1.4 38.4±9.2 9.9±0.2
aNude mice bearing i.p. OVCAR-5 tumours (six per time point) were injected with 10 9g ofc.6equivalent bound to the specified conjugate. After 3 h or 24 h,
animals were sacrificed and samples of tumour and normal tissue removed, weighed, the fluorescence extracted and the peak area of the fluorescence
emission measured. Values are the means of tumour to normal ratios calculated from each of six mice (each tumour fluorescence value was the mean of two
separate tumour samples). Mean ratios were calculated by taking the mean of 24 tumour - normal ratios (for four organs from six mice).
c 6
Pl-cw-succ
Pl ce6
RabbitIgG-pl-c66-succ
Rabbit IgG-pl-c
OC125F(ab')2-pl-cw-succ
OC125F(ab')2-pl-c96
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Figure 5 Relative amounts of ce6fluorescence in i.p. tumour nodules taken
from nude mice injected i.p. with PIC (10glg ofc.6equivalent) after time
shown. Values are means (± s.e.m.) of 12 tumour samples (two separate
tumour samples from each of six mice at each time point). *, after 3 h; L,
after 24 h
Animal model
The predominant clinical manifestation is diffuse, macroscopic
intraperitoneal disease. Tumour deposits cover all serosal surfaces
especially pelvis, subgastrium and peritoneum. Widespread carci-
nomatosis preceded any significant ascites production. Owing to
the extensive presence of macroscopic and microscopic tumour,
itproved impossible to dissect areas ofnormal peritoneum to eval-
uate the uptake ofthe MAbs and PICs by normal peritoneum.
Tumour: normal tissue ratios of 1251
These are shown for six normal organs and for the means of the
ratios for all six organs in Table 1. Also given for comparison are
the values for %ID 1251 per g oftumour. Unmodified OC125F(ab')2
and rabbit IgG are compared with cationic and anionic PICs
prepared from these proteins. The mean ratios obtained with
OC125F(ab')2 and its cationic and anionic PICs are significantly
greater (two to four times) than the corresponding mean ratios
obtained with the equivalent rabbit IgG conjugate and time after
injection (P < 0.01 in each of six cases). At 3 h, the mean ratio for
cationic OCl25F(ab')2-pl-ce6 (5.2 ± 1.0) was significantly greater
than that for unmodified OC125F(ab')2 at 3 h (3.5 ± 0.4, P < 0.05)
and at 24 h (3.2 ± 0.4,P < 0.05) and anionicOC125F(ab')2-pl-c,6-
succ at 3 h (3.3 ± 0.4, P < 0.05) but not at 24 h. However, this ratio
obtained with the cationic OC125F(ab')2-pl-ce6 fell sharply at 24 h
(3.0 ± 0.4, P < 0.05). The mean ratios for 1251 delivered by rabbit
IgG (both unmodified protein and PICs) were found to be signifi-
cantly higher at 3 h than at 24 h (P < 0.05 for all three forms). In
addition, at 3 h the mean ratio from the cationic rabbit IgG PIC
(2.2 ± 0.25) was significantly higher than the anionic rabbit IgG
PIC (1.47 ± 0.1, P < 0.01), but not the unmodified rabbit IgG. The
main difference in organ distribution was the low tumour - kidney
ratio when the i25J was delivered by the cationic OC125F(ab')2-pl-
ce6, which was significantly lower than that from unmodified
OC125F(ab')2 (P < 0.001) and from anionic OC125F(ab')2-pl-ce6-
succ (P < 0.05) at 3 h.
Percentage injected dose per gram of 1251 from
OC125F(ab')2 and rabbit IgG PICs
I25l uptake expressed as the percentage injected dose per gram of
tissue into six normal organs and the mean oftwo tumour samples,
delivered by unmodified OC125F(ab')2 and cationic and anionic
OC125F(ab')2 PICs after 3 h is shown in Figure 3A and after 24 h
in Figure 3B. It can be seen that the amount of 1251 retained not
only in tumour but also in normal organs is highest for unmodified
OC125F(ab')2, lower for the cationic OC125F(ab')2 PIC and
lowest for the anionic OC125F(ab')2 PIC at both time points.
Figure 4A and B shows the percentage injected dose per gram for
i251 delivered by rabbit IgG and its conjugates. The overall values
are significantly lower than those found for the OC125F(ab')2 and,
in addition to the values fortumourbeing lower, the values forskin
are higher.
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Endogenous fluorescence in uninjected mice
It has been reported (Weagle et al, 1988) that mice fed on labora-
tory chow containing chlorophyll have varying amounts of a
chlorin-like metabolite in their gastrointestinal tract and some-
times in their skin. In agreement with these results, we found
chlorin-like fluorescence emission spectra in tissue extracts from
the intestines and skin of non-injected mice. These values were
variable and generally lower than that delivered to these organs by
i.p. injected ce6 derivatives, and the mean values of endogenous
fluorescence peak areas per gram oftissue from nine control mice
were subtracted from the peak areas per gram of skin and intestine
tissue in the mice injected with ce6 conjugates.
Tumour-normal tissue ratios of c06
The tumour to normal tissue ratios of c content measured for four
normal organs (liver, kidney, intestines and skin) and the means of
these four ratios, removed at 3-h and 24-h intervals after i.p. injec-
tion, are shown in Table 2. Also given for comparison are the
absolute fluorescence content for the tumour in peak area per gram.
These are given for ce6 delivered by the cationic and anionic charged
forms ofOC125F(ab')2 PIC, rabbit IgG PIC, polylysine conjugates
and free ce6. Values are not given for the tumour to normal ratios of
spleen and lung, as the amount offluorescence extracted from these
tissues was so low that the ratios would have been unreasonably
high (from 100-10 000). The mean ofthe tumour: normal ratios at 3
h obtained from the cationic OC125F(ab')2 PlC (18.7 ± 4.5) was
significantly higher than that from the anionic OC125F(ab')2PIC
(7.7±2.6, P < 0.05), significantly higherthan cationic pl-ce6 (10.0 ±
2.0, P < 0.05), but not different from cationic rabbit IgG-pl-ce6. At
24 h, the ratio from the cationic OC125F(ab')2PlC (23.1 ± 8.1) was
not significantly different fromthe anionic OC125(ab')2 PIC (18.6 ±
5.8) or from the cationic rabbit IgG-pl-ce6 (30.4 ± 8.4), but was
significantly higher than cationic pl-ce6 (3.6 + 1.6, P < 0.01). The
mean ratio from the anionic OC125F(ab')2PIC at 24 h (18.6 ± 5.8)
was significantly greater than that found from the same PIC at 3 h
(7.7 ± 2.6, P < 0.05), but neither at 3 h nor 24 h did the anionic
OC125F(ab')2 PIC give significantly higher tumour to normal ratios
than the anionic rabbit IgG PIC or the anionic pl-ce6-succ.
Rabbit IgG-pl-ce6-succ
Rabbit IgG-pl-Ce6
Rabbit IgG
OC125F(ab')2-pl-cw6-succ
OC125F(ab')2-PI-c.6
OC125F(ab')2
0 5 10 15 20 25
Mean percentage injected dose of 1251 per gram
Figure 6 Mean values (± s.e.m.) of percentage injected dose of 1251 per gram
of tissue calculated as means of the six values for normal organs and mean
value for two tumour samples from Figures 2 and 3. *, after 3 h;OI, after 24 h
It should be noted that one of the most sensitive normal struc-
tures to i.p. PDT is the intestines (Veenhuizen et al, 1994). In this
case, the tumour to intestine ratios for the cationic OC125F(ab')2
PIC at 3 h (9.7 ± 3.4) and the anionic OC125F(ab')2 PIC at 24 h
(4.0 ± 1.3) were significantly greater than the tumour to intestines
ratios of all species at all time points (P < 0.05) except the anionic
rabbit IgG PIC at 24 h (2.2 ± 1.5).
Relative amount ofc. delivered to tumour by
OC125F(ab')2 and rabbit IgG PICs
Although the tumour to normal ratios obtained with ce6 delivered
by OC125F(ab')2 PICs were not significantly higher than those
found with rabbit IgG PICs for either charge or time point, there
may still be an advantage in using OC125F(ab')2 PICs, if they
deliver a higher amount ofthe PS to the tumour. That this is indeed
so for the cationic conjugates is shown in Figure 5. The uptake
from the OC125F(ab')2 cationic PIC was 3.2 times greater at 3 h
and 3.8 times greater at 24 h than that from the rabbitIgG cationic
PIC (P < 0.05 in both cases). The uptake of ce6 delivered by the
cationic OC125F(ab')2 PIC was also 7.6 times and 2.5 timeshigher
than that from the anionic OC125F(ab')2 PIC at 3 h and 24 h
respectively (P < 0.05 in both cases). Aside from the cationic
OC125F(ab')2 PIG, other species did not give significant differ-
ences except for the anionic OC125F(ab')2 PIC, which at 24 h
delivered 33 times more than anionic pl-ce6-succ (P < 0.01).
DISCUSSION
Conjugation procedures may, in addition to sometimes reducing
the affinity and or the specificity of the MAb for the antigen,
produce structural changes so profound that the fundamental
biochemical trafficking of the MAb is changed. This change may
be either forthe better or for the worse, as far astargeting the cyto-
toxic moiety to the tumour is concerned.
The present study has investigated the biodistribution of
OC125F(ab')2 PICs of opposite charge after i.p. administration in
an i.p. xenograft model ofovarian cancer in nude mice. The biodis-
tribution of 1251-labelled protein was measured independently from
the PS ce6. There are three biodistribution parameters that may
affect theefficacy ofi.p. PDT. These are (1) the maximum concen-
tration ofthe PS in the tumour; (2) the maximum tumour - normal
tissue ratio of PS with respect to the most sensitive normal struc-
ture (thought to be the intestines; (Veenhuizen et al, 1994); and (3)
the maximum penetration depth of the PS into the tumour nodules.
This study has not addressedpoint(3) atall, and hasgainedprelim-
inary data on parameters (1) and (2) with two opposite charged
PICs and two time points after administration.
The cationic OC125F(ab')2 PIC has a marked advantage in deliv-
ering a higher amount of ce6 to the tumour than the anionic PIC,
especially at 3 h. In addition, the cationic OC125F(ab')2 PIC
delivers morece6 (2.5-80 times) than any other species at both time
points. The cationic rabbit PIC also produces tumour-normal tissue
ratios that are remarkably similar to those produced by the cationic
OC125F(ab')2 PIC at both time points, but the absolute amount of
ce6 delivered to the tumour was 3.2 and 3.8 times higher for the
cationicOC125F(ab')2PIC at 3 hand 24 hrespectively. The cationic
OC125F(ab')2 PIC is also the only delivery vehicle, which gives
sizeable tumour to intestine ratios ofce6. It isthought(Veenhuizen et
al, 1994) that the intestines are the most sensitive normal intraperi-
toneal organ tophototoxicity causedduring i.p. PDT.
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It is known that imparting a pronounced positive charge to
macromolecules, including monoclonal antibodies, encourages
their binding to the cell and their rapid internalization (Ryser et al,
1982). Molecules that are internalized into cells by virtue of their
positive charge undergo endosomal processing (Hansen et al, 1993)
and accumulate in lysosomes, where proteolysis may take place.
Pardridge et al (1994a,b) have compared unmodified and cationic
monoclonal antibodies and found much increased endocytosis of
the cationic species. In vivo, it has been shown that cationized IgG
molecules have a much higher organ take-up than the unmodified
form (Triguero et al, 1991).
By comparing the results gained from the ce6 and 1251 measure-
ments, it is possible to gain insights into the extent to which the
MAb is responsible for the tumour targeting, and what is
happening to the constituent parts of the PIC. The data show a
marked separation of the ce6 from the 1251. The ce6 is much more
likely to stay in the tissues directly exposed to peritoneal fluid,
while the 1251 is more likely to travel to distant organs via the blood-
stream or the lymphatics. The extremely low levels of ce6 found in
the lungs and spleen indicate that very little ce6 reaches the blood-
stream compared with 1251. There are three possible ways in which
this separation could happen. Firstly, PICs could be endocytosed
into lysosomes and proteolysed to small peptides and amino acids,
which could then leave the cells and enter the circulation. This has
been demonstrated to occur in vitro (Press et al, 1988) and is
thought to be the most likely mechanism in vivo (Press et al, 1990).
Secondly, the 1251 could be removed from the protein by a deiodi-
nating activity (Smith et al, 1993, 1994), and the free iodide ion
could diffuse rapidly throughout the circulation. Thirdly, the pl-ce6
and pl-c 6-succ are attached to the OC125F(ab')2 via a non-
hindered disulphide bond that has been shown to be susceptible to
in vivo reduction (Carroll et al, 1994). This would separate the ce6
from the 1251 but would leave the latter still in the OC125F(ab')2,
which might then be expected to give higher tumour to normal
ratios of 1251 than ce6, which is the opposite of what is found. If the
cationic conjugates are taken up by i.p. tumour cells via endocy-
tosis and degraded in lysosomes where the 1251 was released and the
ce6 retained, this would explain the higher tumour to normal ratios
ofce6 compared with 1251, and would also be consistent with in vitro
data using these OC125F(ab)2 PICs (Hamblin et al, 1996) and
previous work using conjugates between'251 labelled low-density
lipoprotein and haematoporphyrin (Hamblin and Newman, 1994).
The high ratios but low absolute content of ce6 found for the
cationic and anionic rabbit IgG PICs are also consistent with this
hypothesis. However, it must be stated that the rabbit IgG PICs
were formed from an intact IgG not a F(ab')2 fragment, and this
may lead to different pharmacokinetic parameters. The in vivo
metabolism ofthe PICs could be confirmed by carrying out exper-
iments that looked at the degree to which ce6 and 1251 in various
tissue extracts could be precipitated by trichloroacetic acid.
The mean values of percentage injected dose 125I per gram of
tissue for six normal organs and two tumour samples are shown in
Figure 6. It is apparent that there are significant differences
between PICs in the extent to which 1251 is taken up into organs.
Unmodified OC125F(ab')2 has an uptake that is twice as high (P <
0.01) as cationic OC125F(ab')2 PIC at both time points, while this
uptake in turn is three times (P < 0.005) higher than that from the
anionic OC125F(ab')2 PIC. These differences are not apparent
with the uptake from the rabbit IgG PICs, which seem to deliver
the same percentages of injected dose to tissues regardless of
the charge on the PIC. There is therefore some difference between
the unmodified OC125F(ab')2 PIC and rabbit IgG that causes the
former to be taken up into tissue much more and, in addition,
makes variation in the charge ofOC125F(ab')2 affect the degree to
which it is taken up into tissue. This difference may either be the
fact of antibody antigen recognition or the fact that the MAb is a
F(ab')2 fragment, while the rabbit is an entire IgG molecule. If the
cationic OC125F(ab')2 PIC is endocytosed and subject to lyso-
somal hydrolysis, this explains the higher uptake of ce6 (compared
with the anionic) by the tumour, the higher tissue uptake of 1251 and
also the higher uptake of 125I by the kidneys (without concomitant
ce6), as proteolytic fragments and amino acids are small enough to
be excreted by glomerular filtration (Smith et al, 1993). The high
tissue uptake of the unmodified OC125F(ab')2, however, may not
be by endocytosis and hydrolysis, but by transcytosis across
the mesothelial barrier of the peritoneum (Flessner and Dedrick,
1994) or via diaphragmatic lymphatics (Abernethy et al, 1991)
into the circulation and hence to tumour and other organs. The low
uptake of anionic OC125F(ab')2 is presumably explained by the
negative charge inhibiting the uptake found with unmodified
OC125F(ab')2, and not stimulating endocytosis as seen with the
cationic PIC.
The fact that the tumour-normal ratios of 125I are higher for the
OC125F(ab')2 of both charges than they are for the equivalent
rabbit IgG PICs while the ratios ofce6 are similar, can be explained
ifone assumes that a PIC that binds to a cell owing to MAb antigen
attraction is less likely to be internalized than the same PIC that
binds via charge interaction. Then a greater proportion of the
cationic rabbit IgG PIC that can only bind via charge will be inter-
nalized, degraded and the 1251 lost from the tumour tissue than is
found for the cationic OC125F(ab')2-pl-ce6
The mean tumour-normal (blood, liver, kidney, intestine and
spleen) ratios found in the study by Thedrez et al (1989) using "'In-
labelled intact OC125 injected i.p. into nude mice bearing
OVCAR-3 tumours were higher than those found at similar time
points with our ['25I]OC125F(ab')2 (at 3 h 6.0 ± 1.4 vs 3.5 ± 0.4 and
at 24 h 6.9 ± 2.7 vs 3.2 ± 0.4 respectively). The reasons for this
difference may be the decreased metabolism of "'In-labelled
MAbs, the use of intact IgG or the use of OVCAR-3 cells, which
express more CA125 than OVCAR-5 cells. However, the tumour
to normal ratio of 125I obtained by the cationic PIC at 3 h
(5.2 ± 1.0) is similar to the value found with the IIIIn-labelled MAb
(6.0± 1.4).
In summary, this initial biodistribution study demonstrates a
distinct advantage of administering PICs with a positive charge to
i.p. xenograft model of ovarian cancer. For example, the mean
tumour - normal (blood, liver, kidney, skin and intestine) ratios
reported by Goffet al (1994) for the PS (CMA) delivered by intact
OC125-PGA-CMA were at 6.8 ± 1.4 at 3h and 5.9 ± 0.7 at 24 h,
which are much lower than those found in the present case (18.7 +
4.5 and 23.1 ± 8.1 respectively). For comparison, ratios found with
non-conjugated PS using HpD injected i.p. into mice bearing i.p.
teratoma (Tochner et al, 1986) were 9.3 ± 1.4 at 2 h and 2.4 ± 1.0
at 24 h (tumour: liver, kidney, intestine and muscle), and, using the
present model and i.p. injected liposomal benzoporphyrin deriva-
tive (Molpus et al, 1996a), 1.4 ± 0.4 at 2 h and 2.1 ± 1.0 at 24 h
(tumour - liver, kidney, skin, intestine, peritoneum and spleen).
The tumoricidal efficiency ofthe ce6 will be determined by, among
other factors, whether the photochemistry of ce6 has been affected
by the conjugation, and on the macroscopic and microscopic
site(s) oflocalization ofthe PICs. These questions are underinves-
tigation in our laboratory.
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